NCT07028216 Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
| NCT ID | NCT07028216 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Georgetown University |
| Condition | Anxiety Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-12-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-06-01 with a primary completion date of 2026-12-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will compare the delivery of an 8-week Mindful Self-Compassion training, in-person against video-conference, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder or dysthymia.
Eligibility Criteria
Inclusion Criteria: * Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current * Must score low on self-compassion, as measured by the self-compassion scale * Must understand study procedure and willing to participate in all testing visits, and treatment as assigned * Must be able to give informed consent to the study procedures Exclusion Criteria: * Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit * A serious medical condition that may result in surgery or hospitalization. * A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment * Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview). * Subjects who will be non-compliant with the study procedures. This may include planned travel out of town. * Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial. * Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy). * Individuals who have completed a course of MSC or an equivalent meditation training in the last year. * Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year. * Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and/or labs. * Adults unable to consent * Pregnant women * Prisoners
Contact & Investigator
Elizabeth Hoge, MD
PRINCIPAL INVESTIGATOR
Georgetown University
Frequently Asked Questions
Who can join the NCT07028216 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Anxiety Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07028216 currently recruiting?
Yes, NCT07028216 is actively recruiting participants. Contact the research team at anxietyresearch@georgetown.edu for enrollment information.
Where is the NCT07028216 trial being conducted?
This trial is being conducted at Washington D.C., United States.
Who is sponsoring the NCT07028216 clinical trial?
NCT07028216 is sponsored by Georgetown University. The principal investigator is Elizabeth Hoge, MD at Georgetown University. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.